Ginkgo Bioworks Holdings, Inc.

NYSE•DNA

CEO: Dr. Jason Kelly Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-04-19

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Contact Information

27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States

877-422-5362

www.ginkgobioworks.com

Market Cap

$421.09M

P/E (TTM)

-1.2

1.3

Dividend Yield

52W High

$17.58

52W Low

$5.00

52W Range

14%

Rank66Top 96.8%

1.5

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 1.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$33.40M+0.00%

4-Quarter Trend

EPS

-$1.43+0.00%

4-Quarter Trend

FCF

-$63.00M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Operating Expenses Decline Total operating expenses fell $301.3M to $485.4M in 2025; R&D expenses decreased $180.3M reflecting restructuring.

Net Loss Narrows Net loss improved $234.3M to $(312.8)M in 2025, driven by lower operating costs and no goodwill impairment recorded.

Operating Cash Burn Reduced Net cash used in operating activities decreased $148.5M to $(171.1)M in 2025, reflecting successful cost control measures.

Biosecurity Segment Sale Agreed Entered agreement February 2026 to sell Biosecurity Business for approximately 20% equity stake in Tower Biosecurity.

Risk Factors

Continued Net Losses Expected Company has history of net losses; expects continued losses for foreseeable future, may never achieve profitability or sustain growth.

Critical Supplier Dependency Risks Reliance on limited, single-source suppliers for critical lab supplies exposes business to supply chain delays and cost risks.

Revenue Concentration Risk Significant revenue concentration exists; one Cell Engineering customer accounted for 15% of total 2025 revenue.

Synthetic Biology Technology Risk Rapidly changing synthetic biology technology risks making current platform, programs, and services obsolete or non-competitive.

Outlook

Investing in Tools Offerings Anticipates expenditures exceeding revenue; plans to further invest in and expand proprietary tools offerings and platform capabilities.

Expanding AI/ML Capabilities Continue developing and deploying generative AI and machine learning tools to enhance biological R&D efficiency and throughput.

Need for Future Capital Expects continued net losses, requiring substantial additional capital to fund business development and platform expansion.

Maintain Multi-Class Structure Expects to maintain concentrated voting power via multi-class stock structure to prioritize long-term goals over short-term results.

Peer Comparison

Revenue (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

Gross Margin (Latest Quarter)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
IOVA	$1.31B	-4.1	-54.5%	5.3%
NRIX	$1.30B	-5.4	-57.5%	8.1%
VIR	$1.29B	-2.9	-49.3%	18.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-11.6%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:$41.50M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data